Novelion Therapeutics Inc. announced the appointment of Michael Price as senior vice president and chief financial officer, effective December 4, 2017. Gregory Perry has resigned as CFO of Novelion to pursue other opportunities, and will remain with the company until December 31, 2017 to enable an effective transition. Michael Price was most recently vice president and chief financial officer for Noven Pharmaceuticals Inc.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -4.49% | -0.54% |
2022 | Novelion Therapeutics Inc. Announces Final Cash Distribution, Payable on or About March 31, 2022 | CI |
2020 | Novelion Therapeutics Inc. Announces Management Changes | CI |
- Stock Market
- Equities
- NVLNF Stock
- News Novelion Therapeutics Inc.
- Novelion Therapeutics Inc. Announces Management Changes